TAXIS Pharmaceuticals
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9 Deerpark Dr Ste M, Monmouth Junction, ...Phone Number
(732) 230-3074Website
www.taxispharma.comRevenue
<$5 MillionIndustry
About TAXIS Pharmaceuticals
TAXIS Pharmaceuticals is a clinical-stage company focused on developing investigational therapies to combat antimicrobial resistance, addressing the root causes of the issue and targeting the foundation of bacterial survival. Their product pipeline includes TXA709, an oral anti-MRSA agent, Efflux Pump Inhibitors (EPIs) to enhance existing antibiotics, and Dihydrofolate Reductase Inhibitors (DHFRIs) aimed at treating highly resistant gonorrhea. The company aims to eliminate the threat of antimicrobial resistance across a wide range of infectious diseases, with a vision of a world where such resistance is a thing of the past. Their intended clients include healthcare providers and institutions dealing with infectious diseases and antimicrobial resistance.Explore more
TAXIS Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to TAXIS Pharmaceuticals
Compare insights from companies similar to TAXIS Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
TAXIS Pharmaceuticals Tech Stack
A closer look at the technologies used by TAXIS Pharmaceuticals
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TAXIS Pharmaceuticals
Sign Up For FreeTo access detailed company insights
TAXIS Pharmaceuticals is a clinical-stage company focused on developing investigational therapies to combat antimicrobial resistance, addressing the root causes of the issue and targeting the foundation of bacterial survival. Their product pipeline includes TXA709, an oral anti-MRSA agent, Efflux Pump Inhibitors (EPIs) to enhance existing antibioti... Read More
